Exelixis
EXEL
#1700
Rank
S$13.29 B
Marketcap
$46.56
Share price
0.12%
Change (1 day)
66.30%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024S$9.41 M45.17%
2023S$6.48 M-41.81%
2022S$11.14 M-31.9%
2021S$16.36 M-20.71%
2020S$20.64 M303.63%
2019S$5.11 M-70.5%
2018S$17.33 M8.82%
2017S$15.92 M-17.35%
2016S$19.27 M-75.68%
2015S$79.23 M19.37%
2014S$66.37 M258.49%
2013S$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
S$25.89 MS$55.2 M๐Ÿ‡ฌ๐Ÿ‡ง UK
S$11.64 MS$71.88 M๐Ÿ‡ซ๐Ÿ‡ท France
S$14.45 MS$88.44 M๐Ÿ‡บ๐Ÿ‡ธ USA
S$29.95 MS$0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
S$48.74 MS$0.23 B๐Ÿ‡บ๐Ÿ‡ธ USA
S$70.18 MS$0.32 B๐Ÿ‡บ๐Ÿ‡ธ USA
S$50.21 MS$0.38 B๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.19 MS$1.32 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/AS$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA